Australian scientists and Japanese tech co. in joint bid to improve autism diagnostics
06 Feb 2020
Major Japanese electronics multinational JVCKENWOOD has launched a
with La Trobe University in Melbourne and the Telethon Kids Institute in
Perth to aid early diagnosis of autism spectrum disorder (ASD).
The trial will explore the potential for using JVCKENWOOD’s ‘Gazefinder’
eye-tracking technology as part of the diagnostics process.
Signs of ASD appear in children before they are three years old, but the
condition is often not diagnosed until much later. The trial will involve
200 children aged two to four years.
JVCKENWOOD chose Australia for the trial because the country is well known
for its advanced research into autism.
Gazefinder uses infrared light to track eye movements and gaze patterns,
and to identify unique visual eye patterns in individuals. The analysis
takes around two minutes.
According to Dr Kristelle Hudry, lead researcher from La Trobe’s School of
Psychology and Public Health, the Gazefinder technology has the potential
to streamline the diagnostic process and build confidence in clinicians,
resulting in earlier diagnosis in children.
People with ASD have lifelong difficulties with daily living activities and
social functioning. Currently there is no established pharmaceutical or
JVCKENWOOD is funding the research. It aims to implement the results of the
study by obtaining Therapeutic Goods Administration (TGA) approval for use
of Gazefinder as a medical device to support ASD diagnosis in Australia.
Austrade’s Japan office has been working closely with JVCKENWOOD since 2016
and was instrumental in connecting the company with its Australian clinical
Based in Yokohama, JVCKENWOOD is responsible for the global brands JVC and
KENWOOD, with products ranging from wireless headphones and dashcams to
medical imaging devices. It has almost 17,000 employees across a network
spanning the Americas, Europe, Asia-Pacific, China, Russia and the Middle